Evidence map›Paper›PMID 34559250›Full record

ArticleArchives of toxicology2021

The codification of hazard and its impact on the hazard versus risk controversy.

John E Doe, Alan R Boobis, Samuel M Cohen, Vicki L Dellarco, Penelope A Fenner-Crisp, Angelo Moretto, Timothy P Pastoor, Rita S Schoeny, Jennifer G Seed, Douglas C Wolf

Abstract readLetter
In one paragraph

Article in Archives of toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John E DoeSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. j.e.doe@ljmu.ac.uk.ORCID 0000-0001-5393-1421
Alan R BoobisNational Heart & Lung Institute, Hammersmith Campus, Imperial College London, London, W12 0NN, UK.
Samuel M CohenDepartment of Pathology and Microbiology, Havlik-Wall Professor of Oncology, University of Nebraska Medical Center, Omaha, NE, 68198-3135, USA.
Vicki L DellarcoIndependent Consultant, Silver Spring, MD, 20901, USA.
Penelope A Fenner-CrispIndependent Consultant, North Garden, VA, 22959, USA.
Angelo MorettoDipartimento di Scienze Cardio-Toraco-Vascolari e Sanità Pubblica, (Department of Cardio-Thoraco-Vascular and Public Health Sciences), Università degli Studi di Padova, Padua, Italy.
Timothy P PastoorPastoor Science Communication, LLC, Greensboro, NC, 27455, USA.
Rita S SchoenyRita Schoeny LLC, Washington, DC, 20002, USA.
Jennifer G SeedIndependent Consultant, Alexandria, VA, 22301, USA.
Douglas C WolfSyngenta Crop Protection LLC, Greensboro, NC, 27419, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long running controversy about the relative merits of hazard-based versus risk-based approaches has been investigated. There are three levels of hazard codification: level 1 divides chemicals into dichotomous bands of hazardous and non-hazardous; level 2 divides chemicals into bands of hazard based on severity and/or potency; and level 3 places each chemical on a continuum of hazard based on severity and/or potency. Any system which imposes compartments onto a continuum will give rise to issues at the boundaries, especially with only two compartments. Level 1 schemes are only justifiable if there is no variation in severity, or potency or if there is no threshold. This is the assumption implicit in GHS/EU classification for carcinogenicity, reproductive toxicity and mutagenicity. However, this assumption has been challenged. Codification level 2 hazard assessments offer a range of choices and reduce the built-in conflict inherent in the level 1 process. Level 3 assessments allow a full range of choices between the extremes and reduce the built-in conflict even more. The underlying reason for the controversy between hazard and risk is the use of level 1 hazard codification schemes in situations where there are ranges of severity and potency which require the use of level 2 or level 3 hazard codification. There is not a major difference between level 2 and level 3 codification, and they can both be used to select appropriate risk management options. Existing level 1 codification schemes should be reviewed and developed into level 2 schemes where appropriate.

Indexed as

CarcinogenesisEuropean UnionHazardous SubstancesHumansMutagenesisReproductionRisk AssessmentRisk ManagementHazardous Substances

Identifiers

PMID34559250
PMCPMC8492552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.